Dr. Singh has over 15 years of experience in employing powerful tools in molecular biology, single-cell biology, bioinformatics, next-generation sequencing, machine learning, and computational biology to decode the genome sequences and epigenetic signatures driving cellular function, gene regulation and diseases/cancer pathogenesis.
Dr. Singh's lab aims to decode the epigenomic/enhancer rewiring that drives dry Age-related macular degeneration (dAMD) (that leads to vision loss) using human retinal organoid models by exploring the role of inflammation drivers, epigenetic clock, histone variants, transcriptional reprogramming and AMD-specific single-nucleotide polymorphisms (SNPs). As there are no therapeutics available for dAMD, therefore Dr. Singh lab using computational modeling of dAMD epigenetic mechanisms and organoid models will develop drugs and potential therapies for dAMD clinical application.
Projects in Dr. Singh lab are aimed at reducing the metastatic cancer deaths by pinpointing key common epigenetic drivers and rewired enhancers in Uveal Melanoma (UM) i.e. ocular tumor and other cancers with high metastatic instances e.g. high grade serous ovarian cancer (HGSOC). Also, Dr. Singh lab aims to validate new epigenetic therapeutic strategies using Zebrafish UM model and develop methods for early detection of metastasis using cell-free DNA.
Tran H, Singh G, Lee H, Yap D, Lee E, Daniels W, Farhia Kabeer, O’Flanagan CH, Au V, Vliet MV, Lai D, Zaikova E, Beatty S, Kong E, Fan S, Chan J, Dang HQ, Ruiz T, Cerda V, Roth A. Somatic copy number mutations contribute to fitness in transplantation models of spontaneous human breast cancer metastasis. bioRxiv. doi: 10.1101/2025.10.27.684911